Optimal Vector and Delivery Route Selection

Because of the resources available at Dr. Wilson’s Gene Therapy Program, we are able to focus on unique aspects and therapy goals for a given indication and screen a variety of AAVs in non-human primates to choose the optimal capsid and route of delivery to best meet the clinical needs of the patient.

Improved tissue / cell-type targeting translating to reduced toxicity

Higher efficiency of transduction, allowing for improved efficacy

Lower rate of pre-existing neutralizing antibodies